The Latest Breaking News on Pharma

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

Drugs regulator Drugs Controller General of India has directed States and Union Territories to keep vigil on sale and distribution of falsified versions of two drugs, liver medication Defitelio and Takeda’s cancer drug Adcetris after alerts from World Health Organization

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

The pharmaceutical industry’s prospects look bright, fueled by a rapidly aging population, the rising prevalence of chronic diseases, consistent R&D efforts backed by government funding, and digital transformation. Pharma stocks Relay Therapeutics (RLAY) and Perrigo Company (PRGO) should benefit from the industry tailwinds. But let’s find out which stock holds…

DCA officials in Andhra Pradesh have identified spurious drugs worth over ₹1 crore in Visakhapatnam, Tirupati, Kadapa, Vijayawada and other cities.

Drugs Control Administration busts spurious drug racket in Vijayawada. Fake drugs falsely labelled as products of reputed pharma companies were found. These drugs can cause severe health damage and even death. FIR registered against two persons under IPC sections. 24 samples sent to Drug Control Lab, 6 declared sub-standard. Original…

Flora Growth (FLGC) entered a new partnership recently to grow its presence in Europe. Moreover, as the European Union moves toward de-scheduling narcotics, is this the right time to scoop up FLGC shares? Read on.

Previously the Ministry of AYUSH signed an MoU with ASCI for two years to undertake monitoring of AYUSH-related advertisements.

The public notice issued by the apex drug controller on its website said: “The impugned product may be unsafe and its use may result in adverse reaction.”

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….